(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "United States Semaglutide Market Report by Product, Application, Distribution Channel, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets's offering.

The United States Semaglutide Market is expected to expand from US$ 8.17 Billion in 2024 to US$ 17.29 Billion in 2033 at a Compound Annual Growth Rate (CAGR) of 8.68% during 2025-2033. The growth is fueled by rising awareness regarding obesity control, increasing incidence of diabetes, and expanded use of novel therapies. Expansion of the market signifies a high demand for successful weight loss and diabetic control treatments.

Growth Drivers in United States Semaglutide Market

Increased Incidence of Obesity and Type 2 Diabetes

The United States has witnessed a shocking increase in obesity and type 2 diabetes, making semaglutide therapies essential for disease management. Almost half of the American adults are obese, and diabetes strikes millions of people across the country. Semaglutide, under the brands Ozempic and Wegovy, treats both conditions by enhancing glycemic control as well as causing substantial weight loss. Its dual therapeutic value has made it a physician and patient favorite. The growing load of chronic diseases also taxes the health expenditure, necessitating efficient interventions to keep long-term complications at bay.

As lifestyle disorders gain traction, semaglutide use is gaining momentum in the U.S. healthcare system. Its increasing disease prevalence guarantees long-term demand and ranks it as one of the key drivers of growth in the market. The rampant health care and economic expenditures will be just as widespread, with more than 260 million individuals in the USA, more than a third of all children and adolescents, projected to be living with overweight or obesity by 2050. United action and swift investments must be made to change these ominous trajectories and provide an improved future for existing as well as future generations.

Increasing Applications in Weight Management

Though semaglutide was originally developed to treat type 2 diabetes, its ability to aid in weight loss has expanded its use. Clinical trials have confirmed significant weight loss in patients taking semaglutide, and thus, it has been widely used to treat obesity. The FDA approval of Wegovy to treat chronic weight also opened up the drug's potential market to not just diabetic patients but to those with obesity-related illnesses. Increased education on obesity as a medical condition that needs treatment has further fueled demand. Insurers and employers are also realizing the economic benefits of providing weight-loss treatments, increasing semaglutide access.

Strong Physician and Patient Acceptance

Physician and patient acceptance has been a primary driver of semaglutide growth in the U.S. Physicians prefer to prescribe semaglutide because of its better clinical outcomes over older GLP-1 receptor agonists. Patients gain from both enhanced glycemic control and significant weight loss, promoting increased adherence and satisfaction. The weekly injection regimen also increases convenience, lessening treatment fatigue and improving compliance.

Extensive media exposure to semaglutide as a "game-changer" medication has also driven consumer demand, especially for weight management. The strong brand reputation of drugs such as Ozempic and Wegovy has fostered intense brand loyalty in the market. As more patients and healthcare providers recognize its clinical effectiveness and lifestyle benefits, semaglutide continues to see rapid adoption. This positive reception across stakeholders strongly contributes to its ongoing market growth in the U.S.

Challenges in the United States Semaglutide Market

High Cost and Limited Insurance Coverage

Despite its clinical success, the high cost of semaglutide remains a barrier to widespread adoption. Monthly treatment costs are substantial, sometimes several hundred dollars without insurance. Though numerous insurance programs cover semaglutide for the treatment of diabetes, obesity coverage is not consistent. Patients trying Wegovy for weight control frequently must pay out of pocket, which restricts accessibility. The cost detours long-term use, especially for lower-income groups.

Employers and insurers are starting to consider coverage because of the long-term healthcare cost savings that come with treating obesity, but take-up is sluggish. Without wider insurance coverage, affordability continues to be an issue for patients and a stumbling block to increasing market penetration. Price sensitivity in the U.S. healthcare system continues to limit semaglutide's potential despite the high level of demand.

Supply Shortages and Manufacturing Constraints

Another significant issue in the U.S. semaglutide market is chronic supply shortages due to excessive demand and manufacturing constraints. Soaring prescriptions for diabetes and obesity therapy have taxed manufacturing capacities, resulting in periodic stockouts. Patients usually find it difficult to receive regular supplies, interrupting treatment continuity and reducing satisfaction. Production of intricate biologics such as semaglutide is sophisticated and increasing production to match increasing demand is capital-intensive.

These supply concerns also impact healthcare providers, who experience challenges in managing patient expectation and treatment timelines. Although manufacturers are undertaking capacity additions, demand remains ahead of supply, leading to market volatility. Addressing the supply chain difficulties will be essential to providing stable access and achieving long-run market growth in the United States.

Key Attributes

Report Attribute	Details
No. of Pages	200
Forecast Period	2024-2033
Estimated Market Value (USD) in 2024	$8.17 Billion
Forecasted Market Value (USD) by 2033	$17.29 Billion
Compound Annual Growth Rate	8.6%
Regions Covered	United States

Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Semaglutide Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Product
6.2 By Application
6.3 By Distribution Channel
6.4 By States

7. Product
7.1 Ozempic
7.2 Rybelsus
7.3 Wegovy
7.4 Others

8. Application
8.1 Type 2 Diabetes
8.2 Obesity
8.3 Cardiovascular Risk Reduction

9. Distribution Channel
9.1 Retail Pharmacies
9.2 Hospital Pharmacies
9.3 Online Pharmacies

10. Top States
10.1 California
10.2 Texas
10.3 New York
10.4 Florida
10.5 Illinois
10.6 Pennsylvania
10.7 Ohio
10.8 Georgia
10.9 New Jersey
10.10 Washington
10.11 North Carolina
10.12 Massachusetts
10.13 Virginia
10.14 Michigan
10.15 Maryland
10.16 Colorado
10.17 Tennessee
10.18 Indiana
10.19 Arizona
10.20 Minnesota
10.21 Wisconsin
10.22 Missouri
10.23 Connecticut
10.24 South Carolina
10.25 Oregon
10.26 Louisiana
10.27 Alabama
10.28 Kentucky
10.29 Rest of United States

11. Value Chain Analysis

12. Porter's Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes

13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threats

14. Pricing Benchmark Analysis
14.1 Novo Nordisk A/S
14.2 Eli Lilly and Company
14.3 AstraZeneca plc
14.4 Biocon Ltd.
14.5 Johnson and Johnson
14.6 Pfizer Inc.
14.7 AbbVie Inc.
14.8 Sanofi S.A.

15. Key Players Analysis
15.1 Novo Nordisk A/S
15.2 Eli Lilly and Company
15.3 AstraZeneca plc
15.4 Biocon Ltd.
15.5 Johnson and Johnson
15.6 Pfizer Inc.
15.7 AbbVie Inc.
15.8 Sanofi S.A.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN16102025004107003653ID1110205123